Innoviva, Inc. (INVA)

In the past six months, Innoviva's stock has experienced several events. In October 2025, the stock price moved over +1.16% to $17.45 and rose above its 15-day moving average. In August 2025, Innoviva reported its Second Quarter 2025 Financial Results, beating consensus EPS estimates, and announced participation in several investor conferences in September 2025. In July 2025, Cantor Fitzgerald initiated coverage on Innoviva with an "overweight" rating and a $26.00 price target. Oppenheimer initiated coverage with an "outperform" rating and a $45.00 price target in August 2025, while Zacks Research raised Innoviva from a "hold" to a "strong-buy" rating in October 2025. The Goldman Sachs Group began coverage with a "sell" recommendation in September 2025. Innoviva's stock closed at $17.40 on October 22, 2025, 5.33% above its 52-week low of $16.52 set on October 15, 2025, and has a 52-week high of $22.00.

Demand for Innoviva's products can exhibit seasonality, particularly for its respiratory and anti-infective drugs. Respiratory drugs like RELVAR/BREO ELLIPTA and ANORO ELLIPTA typically see increased demand during the monsoon and winter seasons. The anti-infective segment, which includes drugs like XERAVA and XACDURO, also experiences robust growth during monsoon seasons. Demand for critical care drugs, such as GIAPREZA, can surge during pandemics or unexpected increases in the incidence of severe diseases.

Innoviva, Inc. is a diversified biopharmaceutical company focusing on critical care, infectious diseases, and respiratory health, with a portfolio of royalties and other healthcare assets. The company's business model includes a core royalty portfolio from respiratory assets partnered with Glaxo Group Limited (GSK), as well as operating assets in critical care and infectious disease. Major marketed products include RELVAR/BREO ELLIPTA and ANORO ELLIPTA, both generating royalties from GSK, GIAPREZA, XERAVA, XACDURO, and ZEVTERA. The company's development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea, which is in Phase III clinical trials.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company is headquartered in Burlingame, California, USA. Its stock is listed on NASDAQ in the United States, and also on several German exchanges including Berlin, Frankfurt, Munich, Stuttgart, and Dusseldorf, as well as the Berne Stock Exchange in Switzerland, indicating a broader European presence. Institutional shareholders of Innoviva originate from various countries, including the United States, Australia, Canada, and the United Kingdom.

Innoviva's brand reputation in the past year has been positively influenced by several events. Innoviva Specialty Therapeutics' antimicrobial therapies ZEVTERA and XACDURO were nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award. The company has actively participated in and delivered presentations at significant industry events, such as IDWeek 2025, where new analyses from the zoliflodacin pivotal Phase 3 trial were presented. Several analysts have issued favorable ratings and price targets for Innoviva's stock, contributing to a positive perception in the financial community.

Institutional investors and hedge funds own a significant majority of Innoviva's stock, with 99.12% of the stock owned by these entities. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Franklin Resources Inc, Sarissa Capital Management LP, State Street Corp, and American Century Companies Inc. Glaxosmithkline PLC is noted as a significant individual/insider shareholder, owning 50.79% of the company's shares. Other individual/insider owners mentioned include Alexander J. Denner and Jeffrey M. Drazan.